Moberg Pharma AB (publ) (MOB.ST)
SEK 7.08
(-1.8%)
SEK 7.08
(-1.8%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 7.11 Million SEK | 916.43% |
| 2022 | 700 Thousand SEK | 0.0% |
| 2021 | 700 Thousand SEK | 69999900.0% |
| 2020 | 1.00 SEK | 0.0% |
| 2018 | 24.97 Million SEK | -5.97% |
| 2017 | 26.56 Million SEK | -37.1% |
| 2016 | 42.22 Million SEK | 90.2% |
| 2015 | 22.2 Million SEK | 69.01% |
| 2014 | 13.13 Million SEK | 88.5% |
| 2013 | 6.96 Million SEK | -28.45% |
| 2012 | 9.73 Million SEK | 686.04% |
| 2011 | 1.23 Million SEK | 407.03% |
| 2010 | 244.36 Thousand SEK | 0.0% |
| 2009 | - SEK | 0.0% |
| 2008 | - SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 6.57 Million SEK | -7.53% |
| 2024 Q2 | 4.95 Million SEK | -24.73% |
| 2023 Q2 | -2.97 Million SEK | -10.1% |
| 2023 Q3 | -3.64 Million SEK | -22.42% |
| 2023 Q4 | 7.11 Million SEK | 295.36% |
| 2023 FY | 7.11 Million SEK | 916.43% |
| 2023 Q1 | -2.7 Million SEK | -486.0% |
| 2022 Q3 | -1.41 Million SEK | 56.37% |
| 2022 FY | 700 Thousand SEK | 0.0% |
| 2022 Q4 | 700 Thousand SEK | 149.37% |
| 2022 Q1 | -9.2 Million SEK | -1014.53% |
| 2022 Q2 | -3.25 Million SEK | 64.7% |
| 2021 Q2 | -2.85 Million SEK | 73.16% |
| 2021 Q4 | -826 Thousand SEK | 70.27% |
| 2021 FY | 700 Thousand SEK | 69999900.0% |
| 2021 Q1 | -10.63 Million SEK | 0.0% |
| 2021 Q3 | -2.77 Million SEK | 2.7% |
| 2020 Q3 | - SEK | 0.0% |
| 2020 Q1 | -44.72 Million SEK | -4472000166.64% |
| 2020 FY | 1.00 SEK | 0.0% |
| 2020 Q4 | - SEK | 0.0% |
| 2019 Q4 | 1.00 SEK | 0.0% |
| 2019 Q1 | - SEK | -100.0% |
| 2019 Q2 | - SEK | 0.0% |
| 2019 Q3 | - SEK | 0.0% |
| 2018 Q2 | 20.34 Million SEK | -24.83% |
| 2018 FY | 24.97 Million SEK | -5.97% |
| 2018 Q4 | 24.97 Million SEK | 10.4% |
| 2018 Q3 | 22.62 Million SEK | 11.22% |
| 2018 Q1 | 27.06 Million SEK | 1.88% |
| 2017 Q2 | 42.13 Million SEK | -22.33% |
| 2017 Q1 | 54.24 Million SEK | 28.46% |
| 2017 FY | 26.56 Million SEK | -37.1% |
| 2017 Q4 | 26.56 Million SEK | 2.89% |
| 2017 Q3 | 25.81 Million SEK | -38.73% |
| 2016 Q2 | 17.2 Million SEK | -26.0% |
| 2016 Q3 | 38.68 Million SEK | 124.78% |
| 2016 Q4 | 42.22 Million SEK | 9.16% |
| 2016 FY | 42.22 Million SEK | 90.2% |
| 2016 Q1 | 23.25 Million SEK | 4.76% |
| 2015 Q4 | 22.2 Million SEK | 19.19% |
| 2015 Q3 | 18.62 Million SEK | 21.8% |
| 2015 FY | 22.2 Million SEK | 69.01% |
| 2015 Q1 | 18.08 Million SEK | 37.72% |
| 2015 Q2 | 15.29 Million SEK | -15.46% |
| 2014 Q4 | 13.13 Million SEK | 19.71% |
| 2014 Q3 | 10.97 Million SEK | 19.55% |
| 2014 Q1 | 7.89 Million SEK | 13.26% |
| 2014 Q2 | 9.17 Million SEK | 16.29% |
| 2014 FY | 13.13 Million SEK | 88.5% |
| 2013 Q1 | 7.49 Million SEK | -23.03% |
| 2013 Q3 | 6.88 Million SEK | 7.65% |
| 2013 FY | 6.96 Million SEK | -28.45% |
| 2013 Q4 | 6.96 Million SEK | 1.28% |
| 2013 Q2 | 6.39 Million SEK | -14.74% |
| 2012 Q4 | 9.73 Million SEK | 1277.51% |
| 2012 FY | 9.73 Million SEK | 686.04% |
| 2012 Q3 | 707 Thousand SEK | -31.02% |
| 2012 Q2 | 1.02 Million SEK | 44.37% |
| 2012 Q1 | 710 Thousand SEK | -42.7% |
| 2011 FY | 1.23 Million SEK | 407.03% |
| 2011 Q2 | 227.86 Thousand SEK | -6.75% |
| 2011 Q4 | 1.23 Million SEK | 108.21% |
| 2011 Q3 | 595.08 Thousand SEK | 161.16% |
| 2011 Q1 | 244.36 Thousand SEK | 0.0% |
| 2010 FY | 244.36 Thousand SEK | 0.0% |
| 2010 Q4 | 244.36 Thousand SEK | 0.0% |
| 2009 FY | - SEK | 0.0% |
| 2008 FY | - SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| AcuCort AB | -1.09 Million SEK | 747.407% |
| AlzeCure Pharma AB (publ) | -2508.00 SEK | 283792.185% |
| BioGaia AB (publ) | 181.2 Million SEK | 96.073% |
| Enzymatica AB (publ) | 11.49 Million SEK | 38.125% |
| Enorama Pharma AB (publ) | 4.29 Million SEK | -65.774% |
| Gabather AB (publ) | -1772.00 SEK | 401623.702% |
| Klaria Pharma Holding AB (publ.) | - SEK | -Infinity% |
| Nanexa AB (publ) | 1.91 Million SEK | -272.318% |
| Newbury Pharmaceuticals AB (publ) | 4.99 Million SEK | -42.442% |
| ODI Pharma AB | - SEK | -Infinity% |
| Orexo AB (publ) | 42.4 Million SEK | 83.219% |
| Probi AB (publ) | 116.7 Million SEK | 93.903% |
| Swedencare AB (publ) | 398.1 Million SEK | 98.213% |
| Swedish Orphan Biovitrum AB (publ) | 3.87 Billion SEK | 99.816% |
| Toleranzia AB | -1.34 Million SEK | 630.97% |
| Vivesto AB | - SEK | -Infinity% |